A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Ripretinib (Primary) ; Sunitinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms Intrigue
- Sponsors Deciphera Pharmaceuticals
- 13 Aug 2019 According to an Deciphera Pharmaceuticals Media release, the company announced the commencement of a registered underwritten public offering of $200.0 million in shares of its common stock and intends to use these net proceeds for this trial.
- 02 Aug 2019 According to a Deciphera Pharmaceuticals media release, the company continues to activate sites and and enroll patients. As of July 26, 2019, 45 sites have been activated.
- 11 Jun 2019 According to a Deciphera Pharmaceuticals media release, the company intends to expand the trial and is currently assessing the addition of clinical trial sites in China.